Literature DB >> 31313381

Frontline Science: Abnormalities in the gut mucosa of non-obese diabetic mice precede the onset of type 1 diabetes.

Mariana Camila Gonçalves Miranda1, Rafael Pires Oliveira2, Lícia Torres1, Sarah Leão Fiorini Aguiar1, Natalia Pinheiro-Rosa1, Luísa Lemos1, Mauro Andrade Guimarães1, Daniela Reis1, Tatiany Silveira3, Ênio Ferreira3, Thaís Garcias Moreira1, Denise Carmona Cara4, Tatiani Uceli Maioli5, Brian L Kelsall6, Daniela Carlos7, Ana Maria Caetano Faria1,8.   

Abstract

Alterations in the composition of the intestinal microbiota have been associated with development of type 1 diabetes (T1D), but little is known about changes in intestinal homeostasis that contribute to disease pathogenesis. Here, we analyzed oral tolerance induction, components of the intestinal barrier, fecal microbiota, and immune cell phenotypes in non-obese diabetic (NOD) mice during disease progression compared to non-obese diabetes resistant (NOR) mice. NOD mice failed to develop oral tolerance and had defective protective/regulatory mechanisms in the intestinal mucosa, including decreased numbers of goblet cells, diminished mucus production, and lower levels of total and bacteria-bound secretory IgA, as well as an altered IEL profile. These disturbances correlated with bacteria translocation to the pancreatic lymph node possibly contributing to T1D onset. The composition of the fecal microbiota was altered in pre-diabetic NOD mice, and cross-fostering of NOD mice by NOR mothers corrected their defect in mucus production, indicating a role for NOD microbiota in gut barrier dysfunction. NOD mice had a reduction of CD103+ dendritic cells (DCs) in the MLNs, together with an increase of effector Th17 cells and ILC3, as well as a decrease of Th2 cells, ILC2, and Treg cells in the small intestine. Importantly, most of these gut alterations precede the onset of insulitis. Disorders in the intestinal mucosa of NOD mice can potentially interfere with the development of T1D due the close relationship between the gut and the pancreas. Understanding these early alterations is important for the design of novel therapeutic strategies for T1D prevention. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  ILCs; gut mucosa; oral tolerance; secretory IgA; type-1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31313381     DOI: 10.1002/JLB.3HI0119-024RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

Review 1.  The crucial role of early-life gut microbiota in the development of type 1 diabetes.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Acta Diabetol       Date:  2020-07-25       Impact factor: 4.280

Review 2.  The Role of Intestinal Mucosal Barrier in Autoimmune Disease: A Potential Target.

Authors:  Jia An; Yuqing Liu; Yiqi Wang; Ru Fan; Xiaorong Hu; Fen Zhang; Jinhua Yang; Junwei Chen
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

3.  Differential Outcome between BALB/c and C57BL/6 Mice after Escherichia coli O157:H7 Infection Is Associated with a Dissimilar Tolerance Mechanism.

Authors:  Alan M Bernal; Romina Jimena Fernández-Brando; Andrea Cecilia Bruballa; Gabriela A Fiorentino; Gonzalo Ezequiel Pineda; Elsa Zotta; Mónica Vermeulen; María Victoria Ramos; Martin Rumbo; Marina Sandra Palermo
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

4.  Changes in the gut microbiota: a possible factor influencing peripheral blood immune indexes in non-obese diabetic mice.

Authors:  Yiling Wu; Qi You; Jingjin Fei; Jie Wu
Journal:  Antonie Van Leeuwenhoek       Date:  2021-08-09       Impact factor: 2.271

Review 5.  NOD1 and NOD2 in inflammatory and infectious diseases.

Authors:  Bruno C Trindade; Grace Y Chen
Journal:  Immunol Rev       Date:  2020-07-17       Impact factor: 12.988

6.  Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice.

Authors:  Andrew S Nelson; Massimo Maddaloni; Jeffrey R Abbott; Carol Hoffman; Ali Akgul; Christina Ohland; Raad Z Gharaibeh; Christian Jobin; Todd M Brusko; David W Pascual
Journal:  Sci Rep       Date:  2020-04-09       Impact factor: 4.379

Review 7.  Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art.

Authors:  Marilena Durazzo; Arianna Ferro; Gabriella Gruden
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241

8.  Modulation of Intestinal ILC3 for the Treatment of Type 1 Diabetes.

Authors:  Ivana Stojanović; Tamara Saksida; Đorđe Miljković; Nada Pejnović
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

9.  The DNA Sensor AIM2 Protects against Streptozotocin-Induced Type 1 Diabetes by Regulating Intestinal Homeostasis via the IL-18 Pathway.

Authors:  Jefferson Antônio Leite; Gabriela Pessenda; Isabel C Guerra-Gomes; Alynne Karen Mendonça de Santana; Camila André Pereira; Frederico Ribeiro Campos Costa; Simone G Ramos; Dario Simões Zamboni; Ana Maria Caetano Faria; Danilo Candido de Almeida; Niels Olsen Saraiva Câmara; Rita C Tostes; João Santana Silva; Daniela Carlos
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

Review 10.  Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.